Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Vachhani · SciRah

Researcher profile · Semantic Scholar

P. Vachhani

Share profile

P. Vachhani — researcher profile on SciRah

h-index: 24
Works: 228
Citations: 2,809

Most-cited papers

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
M. Litzow, Zhuo-Xin Sun, Ryan J. Mattison, E. Paietta +38 more
2024New England Journal of Medicine204 citations Open access
Semantic Scholar
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
E. Jabbour, H. Kantarjian, I. Aldoss, P. Montesinos +17 more
2024Journal of the American Medical Association (JAMA)124 citations Open access
Semantic Scholar
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
F. Ravandi, M. Subklewe, R. Walter, P. Vachhani +15 more
2024Leukemia and Lymphoma35 citations Open access
Semantic Scholar
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis.
A. Tefferi, G. Barosi, Francesco Passamonti, J. Hernández-Boluda +34 more
2024Blood32 citations Open access
Semantic Scholar
Interferons in the treatment of myeloproliferative neoplasms
P. Vachhani, J. Mascarenhas, P. Bose, Gabriela S. Hobbs +8 more
2024Therapeutic Advances in Hematology28 citations Open access
Semantic Scholar
A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis
P. Vachhani, Peter Tan, A. Watson, Shang-Ju Wu +19 more
2025Haematologica13 citations Open access
Semantic Scholar
Real-World Evidence of Treatment-Free Remission Strategies and Outcomes in Chronic Myeloid Leukemia
Garrett Bourne, Kendall Diebold, Greg Bascug, Joshua Knapp +7 more
2025Cancers11 citations
Semantic Scholar
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review
P. Vachhani, R. Mesa, John Mascarenhas, R. Rampal +9 more
2025Haematologica10 citations Open access
Semantic Scholar
A novel application of XPO1 inhibition for the treatment of myelofibrosis
Megan Metzger, Zachary M. Avigan, P. Vachhani, Julian A. Waksal +1 more
2024Blood neoplasia10 citations Open access
Semantic Scholar
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
P. Bose, H. Ali, H. Al-Ali, V. García-Gutiérrez +20 more
2026Journal of Clinical Oncology6 citations Open access
Semantic Scholar
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial
L. Masarova, Brandi N. Reeves, F. El Chaer, Lynda Foltz +27 more
2025Frontiers in Medicine6 citations Open access
Semantic Scholar
Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial
Jeanne M. Palmer, Jonathan How, P. Bose, P. Vachhani +13 more
2025Blood5 citations
Semantic Scholar
Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis
John Mascarenhas, J. Scandura, V. Gupta, Kazuya Shimoda +34 more
2025Blood5 citations
Semantic Scholar
Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
G. Mannis, C. Abboud, N. Daver, G. Murthy +14 more
2025eJHaem5 citations Open access
Semantic Scholar
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
J. Watts, A. Hunter, Alessandro Vannuchhi, V. Gupta +18 more
2024Blood5 citations
Semantic Scholar
Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
D. DeAngelo, J. Gotlib, V. Pullarkat, P. Vachhani +23 more
2024Blood5 citations
Semantic Scholar
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib
P. Vachhani, Abdulraheem Yacoub, R. Rampal, Terrence Bradley +10 more
2026Future Oncology4 citations Open access
Semantic Scholar
Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials
F. Palandri, Casey L. O'Connell, P. Vachhani, D. Mclornan +8 more
2025Blood4 citations
Semantic Scholar
PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study
N. Grieselhuber, P. Baratam, A. Advani, A. Yacoub +15 more
2024Blood4 citations
Semantic Scholar
Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
Xiao-Min Zhong, K. Roberts, L. Montefiori, Zhuo-Xin Sun +46 more
2025Blood3 citations
Semantic Scholar
Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Lindsay A. M. Rein, Nathan A. Boggs, P. Bose, Brian D. Modena +53 more
2025Blood3 citations Open access
Semantic Scholar
Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study.
Justin M. Watts, A. Vannucchi, Anthony Hunter, V. Gupta +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
Kendall Diebold, Devan Parker, Sarah Worth, M. Espinoza-Gutarra +6 more
2025eJHaem3 citations Open access
Semantic Scholar
Investigational drugs in early phase trials for myelofibrosis
Sankalp Arora, P. Vachhani, P. Bose
2024Expert Opinion on Investigational Drugs3 citations Open access
Semantic Scholar
Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
Garrett Bourne, Kendall Diebold, M. Espinoza-Gutarra, Zaid Al-Kadhimi +5 more
2024Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis3 citations
Semantic Scholar
Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
G. Mannis, N. Podoltsev, D. Jeyakumar, Justin M. Watts +10 more
2025Blood2 citations
Semantic Scholar
Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study
Lindsay A. M. Rein, F. El Chaer, J. Yuda, J. Scandura +38 more
2025Blood2 citations
Semantic Scholar
An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis
Andrew T. Kuykendall, Douglas Tremblay, Anthony Hunter, P. Vachhani +14 more
2025Blood2 citations
Semantic Scholar
Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with intermediate and adverse risk acute myeloid leukemia.
T. Mudd, Kendall Diebold, Katherine Parks, Maris Hardee +8 more
2025Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis2 citations
Semantic Scholar
Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis
P. Vachhani, Paola Guglielmelli, Jennifer Repp, J. Hamer-Maansson +2 more
2025Leukemia and Lymphoma2 citations Open access
Semantic Scholar
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial
A. Ashaye, Ling Shi, I. Aldoss, P. Montesinos +11 more
2025Leukemia2 citations Open access
Semantic Scholar
Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
Peter Tan, R. Baker, Sung-Eun Lee, A. Watson +14 more
2024Blood2 citations
Semantic Scholar
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.
P. Vachhani, V. Gupta, F. Palandri, Purvi Suthar +3 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
N. Podoltsev, Zhuo-Xin Sun, M. Litzow, E. Paietta +39 more
2024Blood2 citations
Semantic Scholar
Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
Jeremy Digennaro, George Concepcion, N. Al Ali, O. Chan +10 more
2024Blood2 citations
Semantic Scholar
Estimated prevalence of polycythemia vera in the United States (2025-2030): SEER analysis with modeled reporting delay.
P. Vachhani, S. Martel, Caleigh M. Sawicki, Cathy Lally +3 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial.
John Mascarenhas, H. Ali, H. Al-Ali, J. García-Gutiérrez +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
D. Sallman, G. Garcia-Manero, Naval G. Daver, C. Abboud +22 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera.
Jeanne M. Palmer, Jonathan How, P. Bose, P. Vachhani +13 more
2026Blood1 citations Open access
Semantic Scholar
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.
Jacqueline S. Garcia, P. Desai, J. Zeidner, O. Wolach +29 more
2026Leukemia and Lymphoma1 citations Open access
Semantic Scholar
Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis
A. Stein, G. S. Guru Murthy, P. Vachhani, Hannah Levavi +6 more
2025Blood1 citations
Semantic Scholar
Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
A. Ashaye, Ling Shi, I. Aldoss, Pau Montesinos +10 more
2025Cancer Medicine1 citations Open access
Semantic Scholar
P775: KMT2A amplification in two adult patients with B-cell acute lymphoblastic leukemia
Min Gao, Yun-Jia Chen, K. Bachiashvili, P. Vachhani +8 more
2025Genetics in Medicine Open1 citations Open access
Semantic Scholar
Momelotinib – a tale of trials, tribulations, transfusion independence, and triumph
Ruchi Desai, P. Vachhani, P. Bose
2025Expert Opinion on Drug Discovery1 citations
Semantic Scholar
Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia
Benjamin McCormick, Omer H. Jamy, M. Espinoza-Gutarra, Ravi Bhatia +6 more
2025Blood1 citations
Semantic Scholar
Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax
R. Mohty, Kendall Diebold, T. Mudd, Maris Hardee +7 more
2025Blood1 citations
Semantic Scholar
Chronic Anaphylaxis With Indolent Systemic Mastocytosis: A Case Report
Sarah Worth, Tracy I. George, Daniel J Shaheen, Maria Roche +1 more
2025Case Reports in Hematology1 citations Open access
Semantic Scholar
A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks
Ross Baker, Chih-Cheng Chen, T. Chen, Stanley Cheung +14 more
2025Blood1 citations
Semantic Scholar
MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis.
I. Aldoss, P. Vachhani, H. Kantarjian, P. Montesinos +16 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer
T. Tashi, H. Oude Elberink, Cem Akin, M. Castells +32 more
2025Blood1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Bose×15
Invite
P. Bose — researcher profile on SciRah
R. Rampal×8
Invite
R. Rampal — researcher profile on SciRah
K. Bachiashvili×7
Invite
K. Bachiashvili — researcher profile on SciRah
Omer H. Jamy×7
Invite
Omer H. Jamy — researcher profile on SciRah

×7

Invite

F. Palandri — researcher profile on SciRah

Invite

D. DeAngelo — researcher profile on SciRah

James K. McCloskey×6

Invite

James K. McCloskey — researcher profile on SciRah

Francesco Passamonti×6

Invite

Francesco Passamonti — researcher profile on SciRah

M. Espinoza-Gutarra×6

Invite

M. Espinoza-Gutarra — researcher profile on SciRah

Sravanti Rangaraju×6

Invite

Sravanti Rangaraju — researcher profile on SciRah

Invite

L. Masarova — researcher profile on SciRah

Kendall Diebold×5

Invite

Kendall Diebold — researcher profile on SciRah